about
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemiaJAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation.CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.Targeted therapy in haematological malignancies.Hurdles toward a cure for CML: the CML stem cell.Thrombosis and hemostatic abnormalities in hematological malignancies.Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.Laboratory and clinical risk assessment to treat myelodysplatic syndromes.Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma.Neutrophil-specific granule deficiency.Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.Assessment of physical activity in an outpatient obesity clinic in southern Italy: results from a standardized questionnaire.Novel epigenetic therapies in hematological malignancies: Current status and beyond.SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitroRestricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population studyContrasting requirements during disease evolution identify EZH2 as a therapeutic target in AMLGingival infiltration in acute monoblastic leukaemiaCortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemiaHemophagocytosis and relapsed peripheral T-cell lymphomaMultiple splenic calcificationsThe evolving management of a rare lymphoproliferative disorder-T-cell prolymphocytic leukemiaCohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignanciesA randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
P50
Q26865149-01383260-EC9F-4089-811D-D1AD83BACC6AQ34106870-7CE00432-BA80-4649-840D-5B63756C1A7BQ34543038-3437B71E-E4D0-4529-BBB1-08D5EAABC5A6Q36080675-3DE116F6-84DC-4AF4-8569-4F38F158FB91Q36508924-5653E5AC-9356-4DB3-88ED-FC75816736CFQ36697774-91DAEDB7-EB53-4A6B-A3F4-3490670457CEQ37635609-3CA1592C-8856-47EC-864E-454E142C04AFQ37638846-82A93346-31B2-424B-B347-FDA8E7F14347Q37664687-CC68A7BF-9935-4D2B-A83E-B60819D09C88Q37952906-F9365A1F-78B1-48BA-9E98-DA4953A167BDQ38228991-7B9E9FB3-B4FD-4249-9585-4475827E9A83Q38616272-547BC3C7-BB63-4D44-9D19-9D348FBED4A7Q38712277-FE1B6D25-AC33-4D41-A613-C0CB6CBCAC6CQ40619775-C90738B6-F4BA-45FE-9141-765D20688AB2Q44727078-680CCFFE-33DE-4993-905B-1279758A8825Q45047639-28B80420-E127-4272-A310-D85AC35844A7Q47816122-FDA77BDB-7AB9-41FF-B38D-AAD66A721471Q48080576-9D036E68-F681-4273-B4C8-5BF14A0EA38EQ48946028-E4E00E98-B4E7-4217-A919-4E7D5D0822EBQ49791801-56D85B4C-D00A-46FC-9398-5097D906FC5EQ51500708-3CCA4894-9731-4D22-93B9-741B4957CA61Q53122966-B80961A8-A67F-4A65-832D-2F16BB50D554Q60300790-4D65890D-2E45-4629-BAD4-72726DFB5293Q63634229-075B7E1A-EBC3-47C7-AE72-4DD2544FB084Q63634234-7158EFAF-EB69-4B5A-A549-76D0E1308EE0Q64076472-7DEB286D-6550-41CA-B1AF-6C7ACE553060Q81574383-EF477076-ADF9-482C-9369-D678D053B72CQ82593774-E96758F8-8176-4471-965E-7207A53F1FC2Q82660922-948138FC-741A-49FD-8342-0E84E2F25618Q82738087-BB95981C-959E-4E3A-A852-E77553CC553BQ84483360-DA52B687-2063-43AF-BABB-4863B7ECCBB2Q90083145-95777444-3A97-4C72-9884-F769E167183FQ92564574-FA7109B6-3081-407C-AA13-4695876230CB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paolo Gallipoli
@ast
Paolo Gallipoli
@en
Paolo Gallipoli
@es
Paolo Gallipoli
@nl
type
label
Paolo Gallipoli
@ast
Paolo Gallipoli
@en
Paolo Gallipoli
@es
Paolo Gallipoli
@nl
prefLabel
Paolo Gallipoli
@ast
Paolo Gallipoli
@en
Paolo Gallipoli
@es
Paolo Gallipoli
@nl
P106
P1153
22978816500
P31
P496
0000-0001-7254-2253